Finanzen von Celldex Therapeutics Inc (CLDX)CLDXCelldex Therapeutics Inc

Evaluating the bottom line, Celldex Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -366468.18%, while the net margin is -334104.55%. These profitability ratios, combined with a Return on Equity (ROE) of -43.88%, provide a clear picture of how effectively CLDX converts its operational activities into shareholder value.

In the context of the broader market, CLDX competes directly with industry leaders such as MESO and MBX. With a market capitalization of $2.36B, it holds a significant position in the sector. When comparing efficiency, CLDX's gross margin of 100.00% stands against MESO's 143.16% and MBX's N/A. Such benchmarking helps identify whether Celldex Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Celldex has a gross margin of 100% but is currently facing significant net losses, with a net income of -78,685,000 USD in Q1 2026. The forward P/E ratio is 0, indicating no earnings expected in the near term, which may concern some investors.